Beyond the Stigma: Understanding and Managing Antipsychotic-Induced Side Effects
"A practical guide to recognizing and mitigating extrapyramidal symptoms (EPS) for patients on antipsychotics."
Schizophrenia is a long-term mental health condition affecting how a person thinks, feels, and behaves. While the causes are complex, involving both genetic and environmental factors, treatments have greatly improved. Second-generation antipsychotics (SGAs) are frequently used due to their effectiveness in managing symptoms. However, these medications can come with side effects, particularly extrapyramidal symptoms (EPS).
EPS refers to a range of movement-related side effects that can include Parkinsonism (symptoms resembling Parkinson's disease), dystonia (involuntary muscle contractions), dyskinesia (involuntary movements), and oculogyric crises (uncontrolled eye movements). While SGAs are generally considered to have a lower risk of EPS compared to older medications, it remains a significant concern for many patients.
This article explores the nature of EPS, delving into why they occur and what can be done to manage them effectively. We'll discuss treatment strategies and new approaches that minimize the impact on patients' lives, bridging the gap between managing mental health and preserving physical well-being.
Prevalence and Clinical Impact of EPSEs
Antipsychotic medications are central to the pharmacological management of schizophrenia, bipolar disorders, mood disorders with psychotic features, and other psychotic disorders. Their use is frequently associated with extrapyramidal side effects (EPSEs), including parkinsonism, dystonia, dyskinesia, and akathisia. A 2021 systematic review and meta-analysis reported that one in five patients experienced parkinsonism and more than one in ten experienced akathisia. The findings underscore the importance of prevention and early management to preserve the benefits of antipsychotic treatment.
Dose, Monitoring, and Measurement Gaps
Antipsychotic drugs differ in their tendency to cause extrapyramidal side effects, but the relationship between dose and EPS has remained unclear. A 2023 systematic review and dose-response meta-analysis examined antipsychotic dose effects and dopamine D2 receptor occupancy to clarify this issue. Current guidance also emphasizes assessment, monitoring, and documentation of side effects as antipsychotic use increases across psychiatric conditions. However, clinicians have devoted comparatively less attention to screening and documenting motor side effects than to monitoring metabolic effects.
From Early Reactions to Tardive Disorders
Extrapyramidal symptoms became recognized as common adverse effects of first-generation and some second-generation antipsychotics, contributing to nonadherence and treatment discontinuation. Early effects can include acute dystonic reactions, parkinsonism, akathisia, and neuroleptic malignant syndrome, while later effects can include tardive dyskinesia and other tardive movement disorders. The occurrence of extrapyramidal effects is described as directly related to antipsychotic potency. Clinically, EPS encompasses problems such as muscle stiffness, tremors, slowed movements, and excessive unwanted movements.
Why Do Extrapyramidal Symptoms Occur?
EPS primarily arises from the way antipsychotic drugs interact with dopamine receptors in the brain, particularly D2 receptors. Dopamine is a neurotransmitter crucial for motor control, and antipsychotics work by blocking dopamine activity to reduce psychotic symptoms. However, this dopamine blockade can disrupt the delicate balance in brain regions responsible for movement, leading to EPS.
- Dopamine Blockade: Antipsychotics reduce dopamine activity, affecting motor control.
- Medication Type: Older FGAs pose a higher risk compared to newer SGAs.
- Individual Sensitivity: Genetic factors and other medications can influence susceptibility.
Current Evidence on EPS Risk
Recent research continues to describe extrapyramidal side effects as a major problem in schizophrenia treatment, where antipsychotic medications have been the backbone of care for the past 50 years. A 2025 study examining predictors of EPS notes that schizophrenia affects around 1% of the world's population and that evidence about associated factors remains limited. A 2023 umbrella review found that adverse effects are wide-ranging and vary between antipsychotics, based on 32 meta-analyses of randomized trials and observational studies. Current reviews identify drug-induced parkinsonism, akathisia, dystonia, and tardive dyskinesia as important forms of EPS that can cause discomfort, functional impairment, and social withdrawal.
Limits of One-Size-Fits-All Management
Management of antipsychotic-induced parkinsonism commonly begins with considering a dose reduction. Switching from an antipsychotic with a higher risk of symptoms to one with a lower risk can also be effective. When switching is not desirable, concomitant medication is another commonly used approach. Medication-associated EPS are more commonly linked with first-generation typical antipsychotics than with second-generation atypical antipsychotics, although anti-epileptic medicines such as Depakote are also identified as associated medications.
Differences Across Antipsychotic Classes
Atypical antipsychotics show reduced extrapyramidal side effects compared with first-generation drugs. Research has attributed different EPS risks to three antipsychotic classes and has compared partial agonists, second-generation antipsychotics, and other groups in patients receiving long-acting injectable treatment. Comparisons are complicated because antipsychotic treatment meta-analyses have often concentrated on efficacy, where trials are more consistent in assessment and reporting. As a result, side-effect data have received comparatively less attention.
Moving Forward: A Holistic Approach to Treatment
Managing schizophrenia and related conditions requires a comprehensive approach. While antipsychotic medications are essential, addressing potential side effects like EPS is equally important. Open communication between patients, caregivers, and healthcare providers is key to identifying and managing these challenges effectively.
Improving EPS Recognition and Management
Future management work is focused on reducing the burden of extrapyramidal movement disorders associated with antipsychotic treatment. EPS can include tremors, rigidity, bradykinesia, and tardive dyskinesia, and they remain closely linked to certain psychiatric medications. A 2023 review describes EPS as common side effects of second-generation antipsychotics that can negatively affect quality of life. These concerns support continued development of approaches for recognizing and managing symptoms while preserving treatment benefits.
Adherence, Physiology, and Daily Life
A 2026 retrospective single-center real-world study by Shao, Lu, Zhang, and Wang examined the risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia. Its source material describes hyperprolactinemia as a common adverse reaction that can undermine medication adherence and impair physiological functions across multiple body systems. Other research on patients with schizophrenia and related disorders examines how antipsychotic side effects affect attitudes toward medication. Together, these findings place adherence, physical functioning, and patient experience at the center of side-effect management.
The development of newer antipsychotics with different mechanisms of action offers hope for minimizing EPS. Partial dopamine agonists and medications with serotonin receptor modulation can provide symptom relief with a lower risk of motor side effects. However, each individual's response to medication varies, and careful monitoring is always necessary.
Ultimately, the goal is to find a treatment plan that effectively manages mental health symptoms while preserving quality of life. By understanding EPS and utilizing the available strategies, patients can lead fuller, more active lives.